A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 in Patients With Episodic Migraine

Trial Profile

A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 in Patients With Episodic Migraine

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 11 Jun 2017

At a glance

  • Drugs Galcanezumab (Primary)
  • Indications Migraine
  • Focus Therapeutic Use
  • Sponsors Eli Lilly
  • Most Recent Events

    • 11 Jun 2017 Results assessing safety and tolerability presented at the 59th Annual Scientific Meeting of the American Headache Society.
    • 11 Jun 2017 Results (n=187) of post-hoc analysis assessing migraine specific quality of life questionnaire and headache impact test in 120 mg arm, presented at the 59th Annual Scientific Meeting of the American Headache Society.
    • 11 Jun 2017 Results of post-hoc analysis assessing clinical predictors of response to galcanezumab, presented at the 59th Annual Scientific Meeting of the American Headache Society.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top